{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:28:18Z","timestamp":1782534498748,"version":"3.54.5"},"reference-count":57,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T00:00:00Z","timestamp":1508371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Rapid advances in the understanding of the molecular biology, data from translational and clinical trials, and retrospective analyses has influenced the diagnosis and treatment of systemic mastocytosis (\n                    <jats:styled-content style=\"fixed-case\">SM<\/jats:styled-content>\n                    ). Many options have existed for the symptomatic management of\n                    <jats:styled-content style=\"fixed-case\">SM<\/jats:styled-content>\n                    patients, but recent evolution in regards to the molecular underpinnings of this disease and our ability to distinguish clonal mastocytosis from mast cell activation syndrome has changed our treatment paradigm and opened new opportunities for understanding genetic risk, transformation to mast cell leukaemia, and treatment choices. Key to this change has been the discovery of the\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">KIT<\/jats:styled-content>\n                    <\/jats:italic>\n                    mutation and the use of next generation sequencing to evaluate for co\u2010existing molecular mutations that may define the disease course. Careful diagnosis, judicious symptom management and close surveillance of those who may have yet undiagnosed disease is paramount in providing optimal management. In this article, we review the diagnosis and provide a paradigm for the management of\n                    <jats:styled-content style=\"fixed-case\">SM<\/jats:styled-content>\n                    patients.\n                  <\/jats:p>","DOI":"10.1111\/bjh.14967","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T06:12:42Z","timestamp":1508393562000},"page":"11-23","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["How we diagnose and treat systemic mastocytosis in adults"],"prefix":"10.1111","volume":"180","author":[{"given":"Robyn M.","family":"Scherber","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology Oregon Health and Science University Portland OR USA"},{"name":"Department of Hematology and Oncology Mayo Clinic Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Borate","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Oregon Health and Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12606"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12893"},{"key":"e_1_2_11_4_1","unstructured":"Akin C. Gotlib J.(2017).Systemic mastocytosis: Management and prognosis. Available at:https:\/\/www.uptodate.com\/contents\/systemic-mastocytosis-management-and-prognosis. (accessed 31 Jul 2017)"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614743"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.02.010"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2013.09.001"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03944.x"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4213"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.05.003"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2433"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.9565.1"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513098"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12409"},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood.V128.22.1964.1964","article-title":"Inhibitory effects of midostaurin and Blu\u2010285 on myeloid progenitor cells derived from patients with multi\u2010mutated KIT D816V+ advanced systemic mastocytosis [abstract]","volume":"128","author":"Jawhar M.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1182\/blood.V128.22.945.945","article-title":"Impact of molecular markers on response and resistance in midostaurin\u2010treated patients with advanced systemic mastocytosis [abstract]","volume":"128","author":"Jawhar M.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2010.10.004"},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood.V128.22.4783.4783","article-title":"Systemic mastocytosis patient experience from mast cell connect, the first patient\u2010reported registry for mastocytosis [abstract]","volume":"128","author":"Lee P.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21561"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31403-9"},{"key":"e_1_2_11_22_1","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/archderm.1996.03890360013002","article-title":"Diffuse cutaneous mastocytosis. Treatment with oral psoralen plus UV\u2010A","volume":"132","author":"Mackey S.","year":"1996","journal-title":"Archives of Dermatology"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076116"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12469015"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01598.x"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.2.394"},{"key":"e_1_2_11_27_1","unstructured":"National Institute of Health. (2016).Systemic mastocytosis. Available at:https:\/\/rarediseases.info.nih.gov\/diseases\/8616\/systemic-mastocytosis(accessed 16 Dec 2016)."},{"key":"e_1_2_11_28_1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood.V128.22.947.947","article-title":"Incidence and prognostic impact of cytogenetics in combination with molecular aberrations in patients with systemic mastocytosis [abstract]","volume":"128","author":"Naumann N.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.455.323"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24426"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1627"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24426"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.07.004"},{"key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V128.22.1965.1965","article-title":"The multi\u2010kinase inhibitor DCC\u20102618 inhibits proliferation and survival of neoplastic mast cells and other cell types involved in systemic mastocytosis [abstract]","volume":"128","author":"Schneeweiss M.A.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831090-00006"},{"key":"e_1_2_11_36_1","first-page":"359","article-title":"Dermographisme et mastocytose","volume":"43","author":"S\u00e9zary A.","year":"1936","journal-title":"Bulletin of the Society For Dermatology and Syphilis"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-3969"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2014.01.012"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000059404"},{"key":"e_1_2_11_40_1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood.V128.22.396.396","article-title":"Prognostic factors and survival prediction in 1,088 patients with mastocytosis collected in the registry of the European Competence Network on Mastocytosis (ECNM Registry) [abstract]","volume":"128","author":"Sperr W.R.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_11_41_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V126.23.6.6","article-title":"The multi\u2010kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)\/cytarabine (C) induction (ind), high\u2010dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18\u201060 with FLT3 mutations (muts): an international prospective randomized (rand) P\u2010controlled double\u2010blind trial (CALGB 10603\/RATIFY [Alliance]) [abstract]","volume":"126","author":"Stone R.M.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_11_42_1","first-page":"197","article-title":"Systemic mastocytosis: current concepts and treatment advances","volume":"3","author":"Tefferi A.","year":"2004","journal-title":"Current Hematology Reports"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1409760"},{"key":"e_1_2_11_44_1","unstructured":"U.S. Food and Drug Administration. (2017).Midostaurin FDA Approval 2017. Available at:https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm555756.htm(accessed 31 Jul 2017)"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000124"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.05.006"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.2018"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.04.018"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00038-8"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1159\/000048185"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1159\/000328760"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_11_53_1","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1182\/blood.V108.11.3627.3627","article-title":"Dasatinib (Sprycel\u2122) therapy for patients with systemic mastocytosis [abstract]","volume":"108","author":"Verstovsek S.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23380"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00231"},{"key":"e_1_2_11_56_1","first-page":"391","article-title":"Mastocytosis complicating pregnancy","volume":"95","author":"Worobec A.S.","year":"2000","journal-title":"Obstetrics and Gynecology"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.48.2294"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.08.015"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14967","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T15:38:41Z","timestamp":1696001921000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,19]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/bjh.14967"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14967","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732011973.793566951","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,19]]},"assertion":[{"value":"2017-10-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}